Sofiva Genomics Co.,Ltd. (TPEX:6615)
Taiwan · Delayed Price · Currency is TWD 33.70
+0.05 (0.15%)
Aug 19, 2026, 11:59 AM CST
Sofiva Genomics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 379.21 | 385.71 | 453.31 | 466.8 | 495.78 | 508.42 | |
Revenue Growth | -6.67% | -14.91% | -2.89% | -5.85% | -2.49% | 4.00% |
Cost of Revenue | 278.5 | 286.58 | 317.65 | 336.89 | 346.79 | 331.6 |
Gross Profit | 100.71 | 99.13 | 135.66 | 129.91 | 148.99 | 176.81 |
Selling, General & Admin | 112.04 | 122.88 | 129.06 | 136.15 | 135.35 | 130.91 |
Research & Development | 7.28 | 9.98 | 9.98 | 9.64 | 10.34 | 10.8 |
Operating Expenses | 119.33 | 132.87 | 139.03 | 145.79 | 145.2 | 141.57 |
Operating Income | -18.62 | -33.74 | -3.37 | -15.88 | 3.79 | 35.24 |
Interest Expense | -0.69 | -0.85 | -1.11 | -1.29 | -1.49 | -1.74 |
Interest & Investment Income | 1.33 | 1.36 | 1.4 | 1.46 | 0.67 | 0.35 |
Earnings From Equity Investments | 34.15 | 23.3 | 25.35 | 23.67 | 41.9 | 31.05 |
Currency Exchange Gain (Loss) | -0.14 | -0.14 | 0.45 | - | - | - |
Other Non Operating Income (Expenses) | 2.44 | 1.75 | 0.9 | 0.95 | 2.48 | -1.2 |
EBT Excluding Unusual Items | 18.47 | -8.32 | 23.62 | 8.9 | 47.35 | 63.69 |
Gain (Loss) on Sale of Assets | -0.02 | -0.02 | - | - | - | - |
Other Unusual Items | 0.03 | 0.03 | - | - | - | - |
Pretax Income | 18.48 | -8.3 | 23.62 | 8.9 | 47.35 | 63.69 |
Income Tax Expense | 3.77 | 0.55 | 4.49 | -3.02 | 4.2 | 6.92 |
Earnings From Continuing Operations | 14.72 | -8.86 | 19.13 | 11.92 | 43.15 | 56.77 |
Minority Interest in Earnings | -0.49 | -0.51 | -0.7 | -0.4 | -0.38 | 0.21 |
Net Income | 14.23 | -9.36 | 18.43 | 11.53 | 42.78 | 56.98 |
Net Income to Common | 14.23 | -9.36 | 18.43 | 11.53 | 42.78 | 56.98 |
Net Income Growth | - | - | 59.88% | -73.05% | -24.92% | 64.58% |
Shares Outstanding (Basic) | 22 | 22 | 21 | 21 | 21 | 21 |
Shares Outstanding (Diluted) | 22 | 22 | 22 | 21 | 21 | 21 |
Shares Change | 0.43% | -0.23% | 1.28% | -0.04% | 0.40% | -0.43% |
EPS (Basic) | 0.66 | -0.43 | 0.86 | 0.54 | 2.00 | 2.68 |
EPS (Diluted) | 0.66 | -0.43 | 0.85 | 0.54 | 2.00 | 2.68 |
EPS Growth | - | - | 57.52% | -73.02% | -25.30% | 65.26% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 28.15 | 14.2 | 17.77 | 2.69 | -16.4 | 71.91 |
Free Cash Flow Per Share | 1.30 | 0.66 | 0.82 | 0.13 | -0.77 | 3.38 |
Dividend Per Share | - | - | 0.300 | 0.200 | 1.000 | 2.000 |
Dividend Growth | - | - | 50.00% | -80.00% | -50.00% | 42.86% |
Gross Margin | 26.56% | 25.70% | 29.93% | 27.83% | 30.05% | 34.78% |
Operating Margin | -4.91% | -8.75% | -0.74% | -3.40% | 0.76% | 6.93% |
Profit Margin | 3.75% | -2.43% | 4.07% | 2.47% | 8.63% | 11.21% |
Free Cash Flow Margin | 7.42% | 3.68% | 3.92% | 0.58% | -3.31% | 14.14% |
EBITDA | 7.48 | -7.08 | 22.46 | 10.21 | 29.85 | 60.4 |
EBITDA Margin | 1.97% | -1.84% | 4.96% | 2.19% | 6.02% | 11.88% |
D&A For EBITDA | 26.09 | 26.65 | 25.83 | 26.1 | 26.06 | 25.16 |
EBIT | -18.62 | -33.74 | -3.37 | -15.88 | 3.79 | 35.24 |
EBIT Margin | -4.91% | -8.75% | -0.74% | -3.40% | 0.76% | 6.93% |
Effective Tax Rate | 20.38% | - | 19.00% | - | 8.86% | 10.87% |